Revance Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

Revance Therapeutics

08/05/2024 01:07

* Revance Therapeutics Inc  RVNC.OQ   RVNC.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 9
for the period ending March 31 2024
    * The Nashville Tennessee-based  company is expected to
report a
14.8% increase in revenue to $56.634 million from $49.33 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Revance Therapeutics Inc
is
for a loss of 75 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.4%
in the last three months. ​
    * Wall Street's median 12-month price target for Revance
Therapeutics Inc is $12.00​, above​ its last closing price
of $4.38. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.95       -0.72      -0.62     Beat    14.4
 Sep. 30 2023  -0.95       -0.85      -1.63     Missed  -91.1
 Jun. 30 2023  -0.79       -0.78      -0.80     Missed  -2.9​
 Jan. 1 0001   -0.74       -0.70      -0.74     Missed  -5.9
 ​​Jan.        -1.05       -0.95      -0.95     Met     -0.1
 1 0001                                                 
 Sep. 30 2022  -0.91       -0.89      -1.17     Missed  -30.8​
 Jan. 1 0001   -0.89       -0.86      -0.88     Missed  -2.3
 Jan. 1 0001   -0.93       -0.83      -0.94     Missed  -12.6
 This summary was machine generated May 8 at 00:07 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)